Is Parathyroid Hormone (PTH) Replacement Therapy Effective In Treating Patients with Hypoparathyroidism? by Kelly, Kaidden G
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship Student Dissertations, Theses and Papers
12-2016
Is Parathyroid Hormone (PTH) Replacement
Therapy Effective In Treating Patients with
Hypoparathyroidism?
Kaidden G. Kelly
Philadelphia College of Osteopathic Medicine
Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Endocrinology, Diabetes, and Metabolism Commons
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Recommended Citation
Kelly, Kaidden G., "Is Parathyroid Hormone (PTH) Replacement Therapy Effective In Treating Patients with Hypoparathyroidism?"
(2016). PCOM Physician Assistant Studies Student Scholarship. 382.
https://digitalcommons.pcom.edu/pa_systematic_reviews/382
 
 
 
 
 
 
Is Parathyroid Hormone (PTH) replacement therapy effective in 
treating patients with hypoparathyroidism? 
 
 
 
 
 
 
 
Kaidden G. Kelly, PA-S  
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
In Partial Fulfillment of the Requirements For  
The Degree of Master of Science 
In 
Health Sciences – Physician Assistant 
 
 
Department of Physician Assistant Studies 
Philadelphia College of Osteopathic Medicine 
Philadelphia, Pennsylvania 
 
 
 
December 16, 2016 
 
 
 
 
 
 
 
 
 
 ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is 
Parathyroid Hormone (PTH) replacement therapy an effective treatment for patients with 
hypoparathyroidism?”  
 
STUDY DESIGN: Review of a randomized control trial published in 2011, a prospective cohort 
study published in 2013, and a randomized crossover study published in 2012.  
 
DATA SOURCES: All articles used were published in English, and were found in peer-reviewed 
journals using PubMed.  
 
OUTCOMES MEASURED: The need to remove supplemental calcium from the diet, the 
amount PTH was used to maintain a normal range, and the method of PTH delivery (daily 
injections vs. subcutaneous pump).  
 
RESULTS: Sikjaer et al found that patients were able to completely eliminate their daily dose of 
calcium and active vitamin D supplements without developing hypocalcemia compared to a 
placebo group. Cusano et al found that patients were able to reduce supplemental calcium and 
vitamin D significantly for up to four years as compared to a placebo group. Winer et al found 
that patients were able to use less PTH hormone to reduce supplemental calcium and magnesium 
supplementation from the diet.  
 
CONCLUSIONS: The results of the three studies demonstrate that PTH replacement therapy is 
an adequate therapy for managing patients with hypoparathyroidism. In all three studies, PTH 
replacement therapy proved the maintenance of calcium levels in the blood, without 
hypocalcemia or hypercalcemia effects.  This ultimately allowed patients to remove the need for 
supplemental calcium from the diet, or significantly reduce the amount of calcium and vitamin D 
supplements from the diet.  
 
KEY WORDS:  PTH replacement, hypoparathyroidism 
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INTRODUCTION 
 
 Hypoparathyroidism is a chronic endocrine disorder that occurs when there is progressive 
destruction of the parathyroid glands, abnormal development, altered parathyroid hormone 
(PTH) production, or impaired PTH action4. This results in hypocalcemia which has a range of 
clinical manifestations ranging from fatigue, irritability, paresthesias to refractory heart failure, 
laryngeal spasms, and death4.  
 The incidence of hypoparathyroidism most commonly occurs in about 18% of patients 
after undergoing a thyroidectomy, with about 9.5% of those patients becoming symptomatic. The 
risk of developing hypoparathyroidism increases with age, especially for those who undergo a 
total thyroidectomy over the age of 502. A rare cause of hypoparathyroidism is autoimmune, 
which can be isolated or combined with polyglandular autoimmunity type I (PGA-1). Congenital 
causes of hypoparathyroidism include DiGeorge’s Syndrome where the parathyroid glands are 
absent or atrophied5. Transient hypoparathyroidism can be caused by manipulation of the blood 
supply or removal of one or more parathyroid glands during surgery2. Intermittent 
hypoparathyroidism can be a result of parathyroid insufficiency4. 
A good history and physical exam, along with adequate laboratory testing is necessary to 
make the proper diagnosis of hypoparathyroidism. When serum calcium levels are decreased 
(less than 8.5 mg/dL) and serum phosphorous levels are elevated (>5.4 mg/dL), patients will start 
to become symptomatic, which includes fatigue, irritability, restless, and may include 
paresthesias4. If picked up early enough, a PTH immunometric assay can be ordered which will 
reveal a low serum PTH level. Once hypoparathyroidism is diagnosed, they are either treated as 
an acute or chronic patient, depending on severity of symptoms. If the patient is acute, he or she 
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is treated with IV calcium with calcitrol supplementation. If the patient is chronic, he or she will 
require lifelong oral calcium with vitamin D supplementation4.  
 In the United States, the surgical cause of hypoparathyroidism resulted in 8,901 cases 
over a 12-month period from 2007 – 2008, with 75% being transient and 25% being chronic5. 
Currently, the prevalence of hypoparathyroidism in the U.S. is estimated at 60-80,000 patients5. 
While there is no direct measurement of how much money is spent on managing patients with 
hypoparathyroidism, the surgical cause of the disease is measured at approximately $4,6423.  
  Currently, PTH replacement therapy is not approved as monotherapy by the Food and 
Drug Administration in the United States. Calcium and vitamin D supplementation for 
hypoparathyroidism has proven to be effective but require lifelong monitoring and carry a great 
number of adverse reactions not limited to hypercalcemia and kidney stones4. PTH replacement 
therapy may be used as a treatment for patients with hypoparathyroidism4. Hypoparathyroidism 
is the only endocrine disorder in the United States without a single hormone replacement therapy 
as a treatment option4. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not, “Parathyroid 
Hormone (PTH) replacement therapy is an effective treatment for patients with 
hypoparathyroidism?” 
METHODS 
 The population for this study included all patients with hypoparathyroidism. The 
intervention studied was PTH (1-34) or PTH (1-84) replacement therapy. The treatment groups 
of PTH replacement therapy delivered via subcutaneous injections and continuous pump therapy 
were compared with placebo groups or twice daily subcutaneous injections of PTH. The 
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outcomes measured were patient oriented evidence. They included the number of patients who 
were able to remove supplemental calcium from their diet, the lowest amount of PTH necessary 
for subcutaneous pump therapy to maintain normal levels of calcium in the blood, and serum 
calcium and vitamin D levels in the blood. This systematic review includes a randomized control 
trial, a randomized crossover study, and a prospective cohort study.  
 The three studies included in this review were found using PubMed database by the 
author. Keywords included in the search were “PTH replacement therapy” and 
“hypoparathyroidism.” All articles were published in English in peer-reviewed journals. The 
three studies selected were chosen based on their relevance to my clinical question and whether 
or not they included patient oriented outcomes. One article was published in 2012 and the other 
two articles were published in 2011. All studies selected had very similar inclusion and exclusion 
criteria. Inclusion criteria included that the study was randomized, controlled, double blind and 
peer reviewed. Patients had to have had the diagnosis of hypoparathyroidism for at least a year 
and were currently on stable calcium and vitamin D supplements. Exclusion criteria included 
patients who had certain medication use within the timeframe of the diagnosis of 
hypoparathyroidism. The summary of the statistics that were utilized and reported were the mean 
change from baseline, relative benefit increase (RBI), absolute benefit increase (ABI), and the 
numbers needed to treat (NNT). Table 1 displays the demographics and characteristics of the 
included studies in this systematic review.  
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Table 1: Demographics & Characteristics of Included Studies.  
Study Type # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion 
Criteria 
W/
D 
Interventions 
Cusano1 
(2013) 
Prospective 
cohort 
82 25 - 
68 
2 yrs 
hypoparathyroidism 
diagnosis 
Stable regimens of 
supplemental Ca 
and vitamin D for 
at least 6 mo.  
Bisphosphonate 
use w/in 5 years 
or more than 6 
months at a 
time 
Women w/ 5 
years’ 
menopause 
Pts who were 
on HRT, 
SERMs, 
corticosteroids, 
fluoride, Li, 
statin, loops, or 
MTX.  
55 PTH (I-84) 
subcutaneous 
injections 
every day for 
2 years  
Sikjaer6 
(2011) 
Randomized 
control trial 
62 31 - 
78 
Plasma ionized Ca 
and Mg levels w/in 
normal ranges 
Pts with regular use 
of vat. D 
supplements for a 
minimum of 3 
months prior to the 
study 
Women on child-
bearing age if they 
did not plan 
pregnancy and/or 
report use of 
contraception 
Severely 
impaired renal 
patients 
Impaired 
hepatic function 
Pts dx with 
alcoholism or 
chronic drug 
use, malignant 
disease, 
sarcoidosis, 
Paget disease.  
SERM use, 
corticosteroids, 
fluoride, Li, and 
anticonvulsants 
5 PTH (I-84) 
subcutaneous 
injections 
every day for 
6 months  
Winer7 
(2012) 
Randomized 
crossover 
trial 
8 36 - 
54 
Diagnosis of 
postsurgical 
hypoparathyroidism 
x 12 months 
Received calcitrol 
and Ca supplements 
Not included in 
study 
0 PTH (I-34) 
delivered by 
insulin pump 
for 6 months  
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OUTCOMES MEASURED 
 The outcomes measured in this study were based on the number of patients who were 
able to eliminate supplemental calcium from the diet. Other outcomes included were the least 
amount of PTH required to maintain therapeutic serum calcium levels, the method of PTH 
delivery (subcutaneous injections vs continuous infusion pump), and the number of patients who 
were able to reduce the amount of supplemental calcium from their diet. These outcomes were 
measured using serum calcium and vitamin D levels, urine calcium levels, and the amount of 
PTH necessary for delivery.  
RESULTS 
 In the prospective cohort study Cusano et al. 82 patients were treated with PTH (1-84) for 
four years, with continuous monitoring of calcium and vitamin D requirements, serum urinary 
calcium, serum phosphorus, bone turnover markers, and bone mineral density (BMD)1. The 
patients selected were based on the set of inclusion and exclusion criteria as provided in Table 1. 
Of the 82 patients who provided written informed consent to participate in the study, only 27 
patients were followed for the duration of the study and were included in the analysis of data1. 
The most common reason for loss to follow up was logistics of travel and loss to follow up. The 
demographics of the study included patients between the ages of 25 – 68 years with a mean age 
of 51 years, and 74% were women. The two major etiologies of hypoparathyroidism were 
postsurgical and autoimmune disease1. Patients were administered PTH (1-84) at a starting dose 
of 100 mcg subcutaneously every other day. Monitoring was accomplished by a review of 
symptomatology and regular measurements of serum and urine calcium levels1. The levels were 
monitored at baseline three times before treatment and at months 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 30, 
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36, 42, and 481. The primary outcome measured was if whether or not patients could have their 
dose of supplemental calcium and vitamin D requirements reduced or completely eliminated 
from their diet. The data reported was continuous and could not be converted into dichotomous 
data. Table 2 summarizes the data presented in the Cusano et al. study.  
Table 2: Median change of supplemental calcium from baseline  
 Baseline  4 years of PTH therapy  
Supplemental Calcium 
Requirements  
2.7 +/- 3 grams per day  1.7 +/- 3 grams per day  
P = 0.006  
 This study demonstrates that after four years, the patients who received the PTH 
replacement therapy were able to significantly reduce or completely eliminate their daily calcium 
and vitamin D supplements from their diet. The p value is reported at 0.006 which is statistically 
significant, meaning that the intervention of PTH replacement therapy was proven to be effective 
in this study. Throughout the study, there were 11 episodes of mild hypercalcemia in eight 
subjects with the majority of episodes occurring within the first 6 months and resolving with 
adjustment of supplemental calcium and vitamin D. No episodes required hospitalizations. The 
most common adverse reactions reported from patients were musculoskeletal, gastrointestinal, 
and mental and mood.  
 In the randomized crossover trial Sikjaer et al. 62 patients with the diagnosis of 
hypoparathyroidism were randomized to daily treatment with PTH (1-84) or similar placebo for 
24 weeks as add-on therapy to conventional treatment6. The patients were selected based on a set 
of inclusion and exclusion criteria as outlined in Table 1. A total of 5 patients did not complete 
the trial – one patient never started the treatment, two patients dropped out for personal reasons, 
and two patients dropped out as a result of side effects (one reporting nausea and one reporting 
dizziness)6. The only statistically significant adverse reaction of PTH replacement therapy 
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compared with the placebo group was reported to be nausea (p < 0.001)6.  The demographics of 
the study included patients between the ages of 31 and 78 years of age with a mean age of 52 
years, and 86% were females. The major etiology of hypoparathyroidism was postsurgical (94% 
of patients in the study). Patients were randomly assigned to receive a daily self-administered 
subcutaneous injection of either 100 mcg of PTH (1-84) or placebo. According to a predefined 
schedule, daily doses of vitamin D and calcium supplements were titrated down if patients 
developed hypercalcemia (plasma ca+2 > 1.40 mmol/L). Patients were monitored with office 
visits, fasting blood samples, and 24-hour urine samples at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 
24. The primary outcome measured was whether or not patients could completely eliminate the 
need for supplemental calcium and vitamin D from their diet. The data was reported in 
dichotomous form. The data was analyzed in the groups to which they were randomized 
(intention to treat analysis), with less than 5% of the data missing. Tables 3, 4, and 5 summarize 
the results of the Sikjaer et al. study.   
Table 3: Number of patients able to discontinue supplemental calcium intake  
 PTH (n = 32)  Placebo (n=30) 
Number of patients  15 0  
 
Table 4: Efficacy of PTH replacement therapy in eliminating supplemental calcium from diet 
Proportion of 
patients 
eliminating 
supplemental 
calcium on 
placebo 
(CER) 
Proportion of 
patients 
eliminating 
supplemental 
calcium on PTH 
(EER) 
Relative benefit 
increase (RBI) 
Absolute benefit 
increase (ABI) 
Number needed 
to treat (NNT) 
EER- CER 
          CER 
EER - CER 1/ABI 
0 0.469 0 0.469 3 
P < 0.001 
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Table 5: Efficacy of PTH replacement therapy on development of adverse events  
Proportion of 
patients 
experiencing 
nausea on 
placebo 
(CER) 
Proportion of 
patients 
experiencing 
nausea on PTH 
(EER) 
Relative risk 
increase (RRI) 
Absolute risk 
increase (ARI) 
Number needed 
to harm (NNH) 
EER- CER 
          CER 
EER - CER 1/ARI 
0 0.25 0 0.25 4 
P <0.001 
 This study demonstrates that PTH replacement therapy may eliminate the need for 
supplemental calcium and could be a cost-effective treatment option for patients with 
hypoparathyroidism. The ABI displays an increase in treatment effect with the PTH group 
compared with the placebo group. The RBI displays the effectiveness of PTH replacement 
therapy compared with the probability of eliminating supplemental calcium from the diet without 
the therapy. The NNT is calculated to determine the number of patients that need to receive PTH 
replacement therapy in order to reduce the need of supplemental calcium from the diet. In the 
Sikjaer et al. study, only three patients require treatment to have one completely eliminate 
supplemental calcium from the diet. The NNH was calculated to determine the number of 
patients that need PTH replacement therapy in order to experience nausea. Four patients require 
treatment to have one experience nausea as a side effect of PTH replacement therapy compared 
to the control group.  
 In the randomized crossover trial conducted by Winer et al. 8 patients with the diagnosis 
of hypoparathyroidism were used to compare continuous PTH (1-34) delivery, by insulin pump, 
with twice-daily subcutaneous injections. They compared the amount necessary to ensure safe 
and effective management of calcium levels in the serum, and whether or not subcutaneous 
delivery of PTH could be used as an alternative to twice-daily injections. The patients were 
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selected based on a set of inclusion and exclusion criteria as stated in Table 1. All patients 
selected completed the trial. The demographics of the patients selected to participate had 
received a diagnosis of postsurgical hypoparathyroidism for at least 12 months. The mean age 
was 46 years, with a range of 36 – 54 years of age. Patients were randomly assigned, at study 
entry in blocks of four to receive PTH (1-34) initially either by insulin pump or by twice-daily 
injection and were crossed over to the alternate delivery method after the initial 3-month 
treatment evaluation7. Patients were monitored at 0, 3, and 6 months throughout the study via 
four-day inpatient admissions. During these admissions, PTH therapy by pump or injections was 
initiated and dose adjusted before discharge. Subjects were instructed not to alter activity level 
throughout the study, and completed weekly questionnaires, via the study website, that screen for 
symptoms of hypoparathyroidism or adverse events. The primary outcome measured was the 
amount of PTH (1-34) required for adequate management of patients with hypoparathyroidism. 
The data was presented in dichotomous form. The data was analyzed in the groups to which they 
were randomized (intention to treat analysis), and then crossed over. Table 6 summarizes the 
results of the Winer et al. study.  
Table 6: Median change of PTH (1-34) required from baseline  
 Twice-daily injections Insulin pump delivery  
Amount of PTH   37 +/- 14 mcg per day  13 +/- 4 mcg per day   
P < 0.001  
 
 Winer et al. demonstrates that if pump therapy is used to manage PTH delivery in 
patients with hypoparathyroidism, then the amount of PTH required to minimize the 
complications of hypoparathyroidism is less than using the subcutaneous injections of PTH. This 
ultimately results in reducing the cost disparity with PTH replacement therapy7. No serious 
adverse reactions occurred throughout the study. Two patients experiencing transient injection 
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site erythema. At the end of the study, seven of the either patients preferred pump therapy over 
twice-daily delivery due to greater convenience of use.  
DISCUSSION 
 These three studies support the use of PTH replacement therapy as effective in the 
management of patients with hypoparathyroidism. PTH replacement therapy is currently 
approved as an adjunct treatment for management of patients with hypoparathyroidism. The only 
condition in which PTH mono therapy is currently approved by the FDA is osteoporosis2. 
Contraindications for PTH replacement therapy include the diagnosis of hyperparathyroidism, 
hypercalcemia, or patients at a higher baseline risk for osteosarcoma2. Another absolute 
contraindication for therapy also includes Paget disease of the bone, or any type of malignancy 
as hypercalcemia may be a result of the natural course of the disease. Problems with PTH 
therapy in the past include the development of osteosarcomas. PTH replacement therapy has 
been studied in osteoporosis treatment and is proven to produce an accumulation of longer lived, 
apoptosis-resistant osteoblasts on bone surfaces that result in the risk of an osteosarcoma2.  
 Limitations of searching for studies were due to the fact that PTH replacement therapy is 
still new and not very well studied for the treatment of patients with hypoparathyroidism. 
Another major limitation of these three studies were the small study size. In each study, the vast 
majority of patients’ etiology of hypoparathyroidism was due to surgical resection of the thyroid 
gland, therefore limiting data on those with autoimmune or genetic causes of 
hypoparathyroidism. Also, the only study that proved to successfully proved to safely eliminate 
the need of supplemental calcium and vitamin D from the diet was Sikjaer et al. Cusano et al. 
proved that the amount of supplemental calcium and vitamin D can be significantly reduced 
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while on PTH replacement therapy, while Winer et al proved that the delivery method can play a 
role on cost of therapy and amount of PTH necessary for successful treatment.  
CONCLUSION 
 Although further studies are warranted, the three studies strongly suggest that PTH 
replacement therapy can be used as treatment for patients with hypoparathyroidism1,6,7. Each of 
the studies followed the patients for an adequate amount of time although the sample sizes were 
relatively small in each study. However, the results still strongly supported the notion of PTH 
replacement therapy as being effective. Future study is warranted to determine whether or not 
PTH replacement therapy can be used for patients with multiple etiologies (autoimmune, 
genetic) of hypoparathyroidism. Study design could also be manipulated to determine whether or 
not PTH replacement therapy could be used for patients who had a diagnosis of acute 
hypoparathyroidism, as these studies only used patients who had a diagnosis of chronic 
hypoparathyroidism. It would also be beneficial to know the long term side effects of PTH 
replacement therapy as all three studies could not make a comment.  
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